PN200-110(isradipine)是新型钙拮抗剂,在强烈扩血管的剂量下,负性肌力作用甚小。因此,对于治疗各种心血管疾病包括心绞痛、高血压和充血性心力衰竭有价值。本文评价该药对一组严重心力衰竭病人的急性血流动力学效应和提供长期治疗临床效果的初步资料。方法:12例严重心力衰竭病人,心脏指数 <2.5L/min/m~1或肺动脉楔压>15mmHg,开始用药前临床稳定至少一个月,并且在研究期间始终稳定。3个月前有不稳定心绞痛或心肌梗塞史,试验前至少48小时不能停用其他扩血管药物或有不能纠正的瓣膜性心脏病作为心力衰竭原发病因者均被除外。病人被安置在冠心病监护病房,用三腔顶端带气囊的热稀释导管经皮插至肺动脉,测右房和肺动脉(嵌入和非嵌入)压力。应用模拟电子计算机(9520,Edwards实验室)的热稀释技术测定心输出量,以冰冻的5％葡萄糖溶液10ml测试。测值包括平均动脉压,心脏指数、心搏出量指数、外周血管阻力、搏功指数、平均收缩压、肺血管阻力。 PN200-110 (isradipine) is a new type of calcium antagonist, in the strong vasodilator dose, negative inotropic effect is very small. Therefore, it is valuable for the treatment of various cardiovascular diseases, including angina pectoris, hypertension and congestive heart failure. This article assesses the acute hemodynamic effects of this drug in a group of patients with severe heart failure and provides preliminary information on the clinical effects of long-term treatment. Methods: Twelve patients with severe heart failure, with cardiac index <2.5 L / min / m 1 or pulmonary artery wedge pressure> 15 mm Hg, were clinically stable for at least one month before starting treatment and were stable throughout the study period. 3 months ago with unstable angina or a history of myocardial infarction, at least 48 hours before the test can not disable other vasodilators or have irreversible valvular heart disease as the primary cause of heart failure were excluded. The patient was placed in a coronary care unit and percutaneously inserted into the pulmonary artery using a thermodiluted catheter with a balloon at the top of the triple chamber to measure the pressures of the right atrium and the pulmonary artery (both embedded and non-embedded). Cardiac output was measured using a thermodilution technique on an analog computer (9520, Edwards Laboratories) and tested in 10 ml of frozen 5% glucose solution. Measurements included mean arterial pressure, cardiac index, stroke volume index, peripheral vascular resistance, stroke index, mean systolic blood pressure, and pulmonary vascular resistance.